Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification

Journal of the National Cancer Institute

Volumn 107, Issue 10, 2015, Pages

  Shiels, Meredith S ^a   Katki, Hormuzd A ^a   Hildesheim, Allan ^a   Pfeiffer, Ruth M ^a   Engels, Eric A ^a   Williams, Marcus ^b   Kemp, Troy J ^b   Caporaso, Neil E ^a   Pinto, Ligia A ^b   Chaturvedi, Anil K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CXCL1 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; SERUM AMYLOID A; TUMOR NECROSIS FACTOR RECEPTOR 2; CXCL9 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK POPULATION; HUMAN; INFLAMMATION; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPLICATION STUDY; SEX RATIO; SMOKING; SQUAMOUS CELL CARCINOMA; ADVERSE EFFECTS; BLOOD; EARLY CANCER DIAGNOSIS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; ODDS RATIO; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; UNITED STATES;

ADULT; AGED; BIOMARKERS; BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINE CXCL9; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INFLAMMATION; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SERUM AMYLOID A PROTEIN; SMOKING; UNITED STATES;

EID: 84944672421     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv199     Document Type: Article

References (34)

1. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4(4):221-233.
2. Azad N, Rojanasakul Y, Vallyathan V. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J Toxicol Environ Health B Crit Rev. 2008;11(1):1-15.
3. Chaturvedi AK, Gaydos CA, Agreda P, et al. Chlamydia pneumoniae infection and risk for lung cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1498-1505.
4. Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol. 2010;28(16):2719-2726.
5. Engels EA, Wu X, Gu J, et al. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res. 2007;67(13):6520-6527.
6. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011;103(14):1112-1122.
7. Shiels MS, Chaturvedi AK, Katki HA, et al. Circulating markers of interstitial lung disease and subsequent risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2262-2272.
8. Shiels MS, Albanes D, Virtamo J, Engels EA. Increased risk of lung cancer in men with tuberculosis in the alpha-tocopherol, Beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev. 2011;20(4):672-678.
9. Shiels MS, Engels EA, Shi J, et al. Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. Cancer. 2012;118(22):5630-5636.
10. Shiels MS, Pfeiffer RM, Hildesheim A, et al. Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst. 2013;105(24):1871-1880.
11. Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330-338.
12. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418-2429.
13. Bach PB, Gould MK. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. Ann Intern Med. 2012;157(8):571-573.
14. Boiselle PM. Computed tomography screening for lung cancer. JAMA. 2013;309(11):1163-1170.
15. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6 Suppl):273S-309S.
16. Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: The Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306(17):1865-1873.
17. Algeciras-Schimnich A, Bruns DE, Boyd JC, et al. Failure of current laboratory protocols to detect lot-to-lot reagent differences: findings and possible solutions. Clin Chem. 2013;59(8):1187-1194.
18. Harrell FE. Regression Modeling Strategies: with Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer-Verlag; 2001.
19. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-454.
20. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48(4):155-170.
21. Eklund KK, Niemi K, Kovanen PT. Immune functions of serum amyloid A. Crit Rev Immunol. 2012;32(4):335-348.
22. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov. 2010;9(6):482-493.
23. Verbeke H, Geboes K, Van DJ, Struyf S. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta. 2012;1825(1):117-129.
24. Shiels MS, Katki HA, Freedman ND, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst. 2014;106(11):3989-3995.
25. Antoniou KM, Tzouvelekis A, Alexandrakis MG, et al. Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest. 2006;130(4):982-988.
26. Cui A, Anhenn O, Theegarten D, et al. Angiogenic and angiostatic chemokines in idiopathic pulmonary fibrosis and granulomatous lung disease. Respiration. 2010;80(5):372-378.
27. Gao P, Zhang J, He X, et al. Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease. PLoS One. 2013;8(5):e57678.
28. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med. 2013;45(3):291-300.
29. Verbeke H, Geboes K, Van DJ, Struyf S. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta. 2012;1825(1):117-129.
30. Sung HJ, Ahn JM, Yoon YH, et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res. 2011;10(3):1383-1395.
31. Moshkovskii SA. Why do cancer cells produce serum amyloid A acute-phase protein? Biochemistry (Mosc). 2012;77(4):339-341.
32. Hamilton KE, Simmons JG, Ding S, Van LL, Lund PK. Cytokine induction of tumor necrosis factor receptor 2 is mediated by STAT3 in colon cancer cells. Mol Cancer Res. 2011;9(12):1718-1731.
33. Kovalchik SA, Tammemagi M, Berg CD, et al. Variation in lung cancer screening efficacy by lung cancer mortality risk. N Engl J Med. 2013;369(3):245-254.
34. Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lungcancer screening. N Engl J Med. 2013;368(8):728-736.